Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
japanese encephalitis virus vaccine inactivated (Nakayama-NIH strain)
- Development stage
- Discontinued
- Lead developer
- Research Foundation for Microbial Diseases of Osaka University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
JE-VAX is an inactivated Japanese Encephalitis Virus Vaccine prepared from the Nakayama-NIH strain of Japanese encephalitis virus. The vaccine is produced by inoculating mice intracerebrally with the virus, followed by harvesting, formaldehyde inactivation, and purification. It is supplied as a sterile lyophilized powder for subcutaneous injection. The primary indication is prevention of Japanese encephalitis, a mosquito-borne viral infection that can cause severe neurological disease. The mechanism of action involves induction of neutralizing antibodies against the envelope protein of the Japanese encephalitis virus, conferring immunity to infection[1][2][8]. Developed and manufactured by The Research Foundation for Microbial Diseases of Osaka University ("BIKEN"), it was previously widely used but has been discontinued or replaced in many countries due to newer vaccines with improved safety profiles.
- Brand names
- JE-VAX
- Other names
- japanese encephalitis virus vaccine inactivatedjapanese encephalitis vaccine (Nakayama)JE vaccine (Nakayama-NIH strain)
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on japanese encephalitis virus vaccine inactivated (Nakayama-NIH strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on japanese encephalitis virus vaccine inactivated (Nakayama-NIH strain).